ONO Pharmaceutical Wins Approval for Braftovi Combo Therapy in BRAF-Mutant Colorectal Cancer
I'm PortAI, I can summarize articles.
ONO Pharmaceutical Co. Ltd. has received regulatory approval in Japan for BRAFTOVI® capsules combined with cetuximab and chemotherapy to treat BRAF-mutant colorectal cancer. This approval is based on positive Phase 3 BREAKWATER study results, showing improved response rates and progression-free survival. The safety profile remains consistent, with no new concerns. This expands treatment options for BRAF-mutant CRC patients in Japan.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments